



**Alex Loftis, PhD**

**VIDA**  
ventures

**Bio:** Alex is a Senior Associate at Vida Ventures. Before joining Vida's Los Angeles office in 2022, Alex was a life sciences consultant at L.E.K. Consulting in Boston, where he focused on due diligence and corporate strategy for biopharma clients. Prior to that, Alex worked as a Fellow in Vida's Boston office. Alex received his Ph.D. from MIT, where studied antigen-specific tolerance induction, peptide drug discovery, and protein engineering as a Biotechnology Training Program Fellow. He graduated summa cum laude from Washington University in St. Louis with an A.B. in Chemistry.

**Notable Investments:** Alex is a board observer for Avalyn and IconOVir.

**Special Skill:** I used to be a decent basketball player. When I was in grad school, I could still dunk, and on one occasion Michael Gladstone told me I had a 'little KD' thing going, which to this day is probably the most flattering compliment I've been paid. The only dunking I do now is at Hai Di Lao.

**Contact:** LinkedIn- <https://www.linkedin.com/in/alex-loftis-a46256140/>





**Alim Ladha, PhD**

**Bio:** Alim is a Principal at MPM BioImpact where he is responsible for investment identification, due diligence, business development, and company creation activities. Prior to joining MPM BioImpact, Alim completed his Ph.D. in Biological Engineering at the Massachusetts Institute of Technology (MIT) in Feng Zhang's lab at the Broad Institute where he focused on developing new molecular tools for biotechnology including CRISPR-associated transposases, retroelement based genome insertion methods, novel nucleic acid delivery vehicles, and CRISPR-based diagnostics. Prior to MIT, Alim worked on the development of microbiome-based therapeutics at Finch Therapeutics and OpenBiome. Alim received his B.S.E., summa cum laude, in Biomedical Engineering from Duke University.

**Special Skill:** After a long hiatus from golf, I've managed to claw back my scratch handicap. Probably more surprising is that after getting my partner into the game, she's the one dragging me to the golf course whenever we get a chance.

**Contact:** LinkedIn- <https://www.linkedin.com/in/alim-ladha-909902121>





**Amanda Chen,  
PhD**



**Bio:** Amanda is a Senior Associate at Vertex Ventures HC (VVHC), located in Boston, where she helps to execute investments in biotech. Prior to VVHC, Amanda was Manager of Cell Therapy Development at Satellite Biosciences, playing a key role in cell therapy CMC and preclinical operations from tech transfer through Series A, which raised \$110M from Polaris, Lightspeed, aMoon and others. Amanda received her PhD from MIT Biological Engineering; she also holds an MPhil in Chemical Engineering from the University of Cambridge and a BS in Biomedical Engineering (*summa cum laude*) from the University of Rochester.

**Special Skill:** I like to tinker with things in the kitchen! This past year I taught myself to shuck oysters and pleat xiaolongbao (i.e. soup dumplings). I like to think that my fine motor skills from (too many) long hours in tissue culture and animal surgery have been put to good use...

**Contact:** LinkedIn- <https://www.linkedin.com/in/axchen/>





**Aniq Tasnim,  
PhD**

**Bio:** Aniq joined 5AM Ventures in 2023 as an Associate. Prior to joining 5AM, she completed both a postdoctoral fellowship and a Ph.D. in David Ginty's lab in the Neurobiology department at Harvard Medical School. In Dr. Ginty's lab, she studied sensory alterations in mouse genetic models of autism spectrum disorders. She earned her B.A. in Neuroscience from Johns Hopkins University. Aniq is an observer for 5AM portfolio companies Nido Biosciences and CAMP4 Therapeutics, and based out of the Boston, MA office.

**Special Skill:** I would do really well in a blind taste test of the different Celsius flavors.

**Contact:** LinkedIn- <https://www.linkedin.com/in/aniqa-tasnim-7b4181204>





**Artavazd  
Arumov, PhD**



**Bio:** Artie joined the Qiming US team in May 2021 and is based in the Cambridge, MA office. Prior to joining Qiming US, he led business development and therapeutic strategy for early-stage biotech Redesign Science. Prior to Redesign Science, he completed doctorate training at the University of Miami's Miller School of Medicine. His research focused on the development and advancement of novel precision therapeutics for use in lymphoma and the study of fundamental drug resistance mechanisms. He also spent time in clinical research at Memorial Sloan Kettering Cancer Center, where he was responsible for the end-to-end management and operations of a portfolio of breast cancer sponsored and investigator-initiated phase I/II clinical trials. He currently serves as an entrepreneur in residence for U Innovation's Coulter Center for Translational Research.

**Notable Investments:** It's exciting to serve as a board observer at Umoja, a company on the cusp of entering the clinic with a first-in-class in vivo CAR-T modality.

**Special Skill:** An uncanny ability to remember random Pokémon related facts - lots of learned lessons coming from Pokémon video games stemming from childhood!

**Contact:** LinkedIn- <https://www.linkedin.com/in/artavazdarumov/>







**Danjuma  
Quarrless, Ph.D.,  
MBA**



**Bio:** Danjuma serves as an Associate Director at AbbVie Ventures, where he specializes in early-stage biotech investing and ecosystem engagement. Relocating to San Francisco in 2023, he has played a key role in reinvigorating AbbVie’s West Coast venture presence, including his involvement as a board observer for Ambagon and Light Horse. Danjuma’s career at AbbVie began in the Genomics Research Center as a computational biologist, where he spearheaded analytics for major population genomics projects including the UK Biobank and Genomics Finland. His experience expanded through strategic leadership training with rotations in search and evaluation, alliance management, and financial decision modeling. Danjuma holds a Ph.D. in Biomedical Sciences from UC San Diego and an MBA from Kellogg School of Management at Northwestern University.

**Notable Investments:** My contribution to the investment in Light Horse Therapeutics is most notable experience as a board observer and investor. This was the first deal where I led the strategic framing and investment pitch to our organization.


**Special Skill:** I try to function by the phrase, “When you need a friend, it’s too late to make one.” Being memorable and able to forge friendships in this line of work is important. I strive to leave engagements feeling that I’ve made a new friend, even if it’s only one person, instead of establishing loose connections with multiple people.

**Contact:** LinkedIn- <https://www.linkedin.com/in/dquarless/>





**David Yang**




**Bio:** David is a member of the investment team at Lux Capital, focusing on life sciences and healthcare opportunities. Prior to Lux, David was an investor at 8VC where he helped lead life sciences investments and incubations. David started his career at the Broad Institute developing computational methods and high-throughput assays for infectious diseases diagnostics and surveillance.

**Notable Investments:** David has been a board observer for Latus Bio, Atomic AI, Flywheel, Tilda Research, Unlearn AI, Latent Labs and a couple other stealth cos

**Special Skill:** I'm a decent crabber, mediocre fisherman, and a former ballroom dancer.

**Contact:** LinkedIn- <https://www.linkedin.com/in/davidkmyang/>  
Twitter- <https://twitter.com/davidkmyang>





**Harry Won, PhD**



**Bio:** Harry is an Associate focusing on life science investment opportunities across therapeutic areas and development stages. Prior to joining OUP, Harry was a Fellow at Flagship Pioneering, where he developed novel company concepts within therapeutics and sustainability. Before that, he was a Fellow at Vida Ventures, contributing to the diligence process for therapeutics investment opportunities.

During graduate school, Harry focused on developing targeted protein degradation as an antibiotic modality for tuberculosis and this work was selected for presentation at the Harvard Horizons symposium. He also served on the leadership of Nucleate as Director of the Innovation Fellowship. Harry received his Ph.D. in Biological Sciences in Public Health from Harvard University and was supported by the Herchel Smith Graduate Fellowship and the National Science Foundation Graduate Research Fellowship. He also holds a B.S. in Biotechnology from the University of Nebraska at Omaha.

**Notable Investments:** Board Observer, IMMvention Therapeutix

**Special Skill:** I started cooking a lot more during the pandemic and am pretty happy with my Prison Sunday Gravy (as seen in *Goodfellas*).

**Contact:** LinkedIn- <https://www.linkedin.com/in/harimwon/>  
Twitter- <https://twitter.com/harimwon>







**James Buxton, MD**


**Bio:** James joined NEA in 2021 and is currently a Principal on the Healthcare team, focused on investments in the life sciences space. Prior to NEA, James held positions at SR One Capital Management, Morgan Stanley, and New Rhein Healthcare Investors. He began his career as first a physician and then a cardiothoracic surgeon. James received a BSc in surgical and medical sciences from University College London and an MD from University College London Medical School. As a Thouron Scholar, he then earned an MBA from The Wharton School.

**Special Skill:** Keeping a low single digit golf handicap. Although it's beginning to creep up.

**Contact:** <https://www.linkedin.com/in/jbuxton-123>

**NEA**





**Jason Wang, MD**

**Bio:** Jason is a Senior Associate on the Frazier Life Sciences team focused on identifying and evaluating new public investment opportunities. Jason joined the Frazier Life Sciences team in 2024 where he focuses on identifying and evaluating new public investment opportunities. Prior to joining Frazier Life Sciences, Jason was a Principal at Vivo Capital. At Vivo, Jason evaluated public market biotech companies pursuing transformative treatments. In prior roles, Jason served on the business development team at Fortress Biotech, where he helped create new biotech companies including Hepla Sciences, which focuses on treating metabolic diseases. Jason attended medical school at the University of Illinois, where he was awarded an HHMI summer fellowship for basic science research. Jason earned his B.A. in Chemistry and History from the University of Rochester where he spent two years in Robert Boeckman's lab studying small molecules as oncology therapeutics.

**Special Skill:** People say biotech is a marathon not a sprint. I started marathoning in 2019 and ran the Phili Marathon in a time of 2 hours and 39 minutes.

**Contact:** <https://www.linkedin.com/in/jason-wang-3734ab50/>





**Kevin Li, MD**

**Bio:** Kevin is a Principal on the Frazier Life Sciences team and invests in public and late-stage private companies. Kevin joined Frazier Life Sciences in 2021 and focuses on identifying and evaluating investment opportunities for the Public Funds. Kevin was previously a resident physician in Internal Medicine at Stanford University Medical Center, where he was also active in outcomes research in cardiology. Before his medical training, Kevin was a consultant at McKinsey and Company, where he worked with clients in the healthcare and pharmaceutical industries on corporate strategy, growth strategy, and mergers and acquisitions.

He received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry and was a member of Phi Beta Kappa.

**Special Skill:** My tennis forehand can be pretty effective.

**Contact:** <https://www.linkedin.com/in/kvinli>





**Lauren Mifflin,  
PhD, MBA**



**Bio:** Lauren joined the Frazier Life Sciences team in 2023, where she focuses on Company Creation. Prior to joining Frazier Life Sciences, Lauren was a venture partner at 82VS, the venture studio of Alloy Therapeutics. She helped to build biologics companies leveraging Alloy's discovery capabilities, including co-founding a company creating T-cell receptor mimic (TCRm) therapeutics for solid tumor indications. Before her time at 82VS, Lauren was a fellow and 4:59 operating associate at 5AM Ventures, focusing on evaluating investment opportunities and building new life sciences companies. In this capacity, Lauren worked with the founding team of Entrada Therapeutics and was a member of the founding team of Nido Biosciences, spanning strategy, operations and scientific discovery roles. Early in her career, Lauren was a health tech investor at Jump Capital and management consultant at Monitor Group/ Monitor Deloitte. Lauren received her PhD from Harvard University where she studied the therapeutic effects of RIPK1 inhibitors on neuroinflammation in neurodegenerative diseases under Dr. Junying Yuan.

**Special Skill:** In college I was an amateur boxer and still love to spend Sunday mornings at Peter Welch's boxing gym in Dorchester.

**Contact** LinkedIn: <https://www.linkedin.com/in/lmifflin/>  
Twitter: @lemifflin





**Linda Vo, PhD**

**Bio:** Linda joined TRV in 2022 as a Senior Associate. Prior to TRV, she was a Principal Investigator at the Center for Translational Genomics of the Innovative Genomics Institute at UC Berkeley. She guided the growth of the center as the founding lead investigator, with a focus on CRISPR-based genome editing to advance HSC and T cell therapies for blood diseases. Linda completed her PhD in stem cell biology and hematology/oncology at Harvard Medical School/Boston Children's Hospital and postdoctoral training in immunology and genome engineering at UCSF. In addition to her academic background, she has held various consulting roles. At TRV, she is eager to leverage her gene and cell therapy expertise to create innovative companies in the emerging technologies and synthetic biology space.

As the daughter of Vietnamese refugees, Linda is determined to help the most vulnerable patient populations and is proud to work alongside brilliant and passionate colleagues who have the experience and conviction to help make that happen.

**Special Skill:** I'm an exceptional dog birthday planner.

**Contact: LinkedIn-** <https://www.linkedin.com/in/linda-t-vo-phd-90893253/>

Twitter- [https://twitter.com/t\\_lindavo](https://twitter.com/t_lindavo)







**Maurizio Fazio,  
MD PhD**

**Bio:** Maurizio is a senior associate at Atlas Venture where he focuses on building companies that transform patient care by translating innovative science and technologies into novel therapeutics. Prior to joining Atlas, Maurizio completed his PhD in biological and biomedical sciences at Harvard University. His doctoral work in the lab of Dr. Leonard Zon focused on identifying genetic and epigenetic drivers of melanoma progression towards metastasis and drug resistance. While in graduate school, Maurizio was a fellow at Vida Ventures and Flagship Pioneering, and served as HILT Education Innovation Fellow mentoring student-led startups from Harvard & MIT. In addition, he was an instructor at the Harvard Summer School, where he developed and taught courses on cancer biology, regenerative medicine, and gene therapy. Before moving to Boston, Maurizio was a research fellow in the lab of Dr. Scott Armstrong at Memorial Sloan Kettering Cancer Center in New York, investigating novel epigenetic therapies for pediatric leukemia. His research work was supported by the Boehringer Ingelheim Fonds, the American Italian Cancer Foundation, the Armenise Harvard Foundation, and the European Association for Cancer Research. He received his MD cum laude with honor mention from Vita-Salute San Raffaele University in Milan, Italy.

**Notable investments:** Currently Board observer for AAVantgarde bio, Accent Therapeutics, and three Atlas seed-stage stealth companies. Most recent investment: Comanche Biopharma. Most recent build: Co-founder of Atlas stealth newco



**ATLAS VENTURE**

**Special Skill:** *I cook the best pasta and risotto you will find in New England*

**Contact:** <https://www.linkedin.com/in/maurizio-fazio>





**Nil Gural, PhD**

**Bio:** Nil joined Polaris in 2022 and is a senior associate in the firm's New York office. She is focused on biotech and healthcare investments. Prior to joining Polaris, Nil was a manager at Bain & Company's healthcare practice with a focus on pharma and medical devices. Before Bain, she was a part of the initial team at Glympse Bio where she helped develop their platform technology. She currently serves as a Board Observer to EpiBiologics and works with Polaris portfolio companies including Crossbow Therapeutics and Satellite Bio. Nil holds a PhD from the HST program of Harvard & MIT where she was an HHMI fellow and a BS in Biomedical Engineering from Washington University in St. Louis.

**Special Skill:** I can dissect mosquitos at a respectable speed (gift from my PhD days of working on malaria). I'm also a decent self-taught video editor.

**Contact:** <https://www.linkedin.com/in/nilgural>

polarispartners





**Noelle Hutchins,  
PhD**



**Bio:** Noelle joined Omega Funds in 2020. She focuses on private company investments, primarily in the fields of oncology and inflammatory disorders. Noelle is currently a board observer at Anjarium Biosciences and Endeavor Biosciences. Prior to joining Omega, Noelle led scientific strategies and vetted healthcare solutions of an emerging venture of the American Heart Association. She also worked as an independent consultant for TreMonti Consulting, where she conducted due diligence and market analyses, assessed early-stage inventions and advised clients on partnering for commercialization and in-licensing opportunities. In addition, she previously mentored entrepreneurs and startups in Science and Technology as an angel investor with Pipeline Angels. Noelle earned her PhD in Immunology from Brown University, studying the pathobiology of acute liver injury in animal models of sepsis and septic shock. She then completed a postdoctoral fellowship in the Center for Genetics and Host Defense with a Nobel Laureate at UT Southwestern Medical Center to identify novel genes involved with mucosal immunity and gastrointestinal diseases.

**Notable investments:** Board observer roles: Anjarium Biosciences and Endeavor Biomedicines. Upstream Bio, Inc. and Engene, Inc.

**Special Skill:** Prior to COVID-19, I lost 5% of my body fat in the Iron Tribe challenge and I enjoy working out at Burn Boot Camp in Newton, MA (shout out to my coaches and Burn crew; they motivate me at 5:15am!). And when I am not working out, I enjoy listening to 90s/early 2000s hip hop, R&B, and Afrobeats, dancing, sleeping in, and spending time with my family.

**Contact:** <https://www.linkedin.com/in/noelle-hutchins-phd-35b76a12>





**Pablo Lubroth,  
MPhil**

Hummingbird

**Bio:** Pablo leads the biotechnology practice at Hummingbird. Previously, Pablo was an Investment Manager at UKI2S, investing in early-stage cell and gene therapy companies, and worked as a Corporate Development Associate at the gene editing company Horizon Discovery. He holds degrees in Neuropharmacology and Biochemical Engineering from University College London and an MPhil in Bioscience Enterprise from the University of Cambridge.

**Notable investments:** Investments or board positions include Enveda Bio, Amber Bio, Kaleidoscope, Waypoint Bio, Kernal Bio, Serna Bio, Pheiron, Basecamp Research, Automata

**Special Skill:** I asked my partner to describe what my greatest skills are, this is what she wrote: “You climb scary rocks over water and read a lot about things that are complicated. To relax, you binge eat cereal.”

**Contact:** Twitter: <https://twitter.com/pablolubroth>  
LinkedIn: <https://www.linkedin.com/in/pablolubroth/>  
Subscribe to Decoding Bio! <https://www.decodingbio.com/>





**Patrick  
Lundgren, PhD**

**Bio:** Patrick focuses on biotech investments at Hummingbird and leads incubations. He's a big fan of "thoughtfully crazy" people building in bio. He was previously an Associate at Flagship Pioneering where he worked in venture creation to build and originate bioplatfrom companies. Before Flagship, Patrick completed his Ph.D. in immunology at the University of Pennsylvania, publishing 10+ papers including in Cell, Nature, and Nature Metabolism spanning adipocyte biology, immunology, and gut-brain signaling. Patrick also holds an M.Sc. in immunology from the University of Oxford (with Distinction), and a BA in Natural Sciences from the University of Cambridge. A native Swede, Patrick grew up in Malmö, which prepared him well for Boston winters.


**Special Skill:** I'm an ok New England surfer. Favorite spots include Nahant, Narragansett, and "The Wall" by Hampton beach.

**Contact:** LinkedIn- <https://www.linkedin.com/in/patlundgren/>  
Twitter- <https://twitter.com/patrlundgren>

Hummingbird







**Rebecca  
Silberman, PhD**

**Bio:** Rebecca is an Investment Director on the Venture Team at RA Capital Management. Becca's primary responsibilities include identifying compelling opportunities for new company creation and investments in early-stage companies, as well as advising RA's portfolio companies. Becca has a BA in Biology from Colgate University and a PhD in Biology from MIT.

**Notable investments:** Becca is a board observer for Capacity Bio, Imbria, Triana Biomedicines, and Ventus Therapeutics, and is a board director for a couple of RA newcos still in stealth mode

**Special Skill:** Tetris, drawing animals, and recommending novels to people

**Contact:** LinkedIn: <https://www.linkedin.com/in/rebecca-silberman/>

RACAPITAL





**Roman Camarda,  
PhD**

**Bio:** Roman is a Vice President in the Venture Investments group at Novo Holdings US, and based in the San Francisco office. He joined Venture Investments in 2022 as a Senior Associate. Previously, he was a Vice President at Aquilo Capital Management where he focused on publicly traded biotech companies. Earlier, Roman was Lead Translational Scientist at the Buck Institute where he worked with the business development office to create and incubate biotech start-ups. Roman holds a PhD in Biomedical Sciences from University of California, San Francisco, and a BS in Biochemistry and BFA in Photomedia from University of Washington.

**Special Skill:** I grew up in and around restaurants and have a very strong affinity for them. If you're in need of a recommendation, call me.

**novo holdings**  
Investing to benefit people and the planet





**Sahil Chopra,  
PhD**



**Bio:** Sahil is currently a Principal at VVHC, based in San Francisco, where he helps to execute investments in biotech. Prior to VVHC, Sahil was a venture fellow at FundRx and has experience in consulting for immunology-based startups, banks (equity research) and mid-sized biotech firms. Sahil completed his PhD in Biological Sciences from Weill Cornell Graduate School in New York in the lab of Dr. Laurie Glimcher (former Dean of Weill Cornell and the current President and CEO of Dana Farber Cancer Institute) and Dr. Juan Cubillos-Ruiz (Cornell University) where he studied the role of stress responses in immune cells.

**Notable investments:** He is a board observer at Indapta Therapeutics, which is a clinical stage company utilizing a specialized subset of NK cells (called G-NK cells) for the treatment of Non-Hodgkin's Lymphoma and Multiple Myeloma. He was also a board observer at Elevation Oncology (NASDAQ: ELEV), that is developing Antibody Drug Conjugates for Claudin 18.2 positive cancers.

**Special Skill:** I "was" a decent underwater swimmer. Probably lost all my swimming skills in the last decade.

**Contact:** LinkedIn: [www.linkedin.com/in/sahilchopra2612](http://www.linkedin.com/in/sahilchopra2612)





**Shoman Kasbekar**

**Bio:** Shoman is part of the investment team at Foresite Capital, and is focused on opportunities in life sciences and healthcare technology. Shoman came to Foresite from Synthego, a life sciences company building automated platforms for CRISPR genome editing. At Synthego he managed strategy and business development across genome editing technologies, discovery platforms, and therapeutics. Prior to Synthego, Shoman held roles in strategy and finance at DaVita, a healthcare company serving over 200,000 patients with kidney disease. At DaVita, Shoman was a part of the Redwoods Leadership program, and received a DaVita Star award for exceptional achievement. Shoman has also held roles at Sharecare, a leading digital health company, and at the Vanderbilt Technology Transfer & Commercialization center. In addition to his work with Foresite Capital, Shoman is a member of the strategic alliances team at the Rare Genomics Institute, a non-profit dedicated to helping rare disease patients and their families find a cure. Shoman received his B.E. in Biomedical Engineering from Vanderbilt University.

**Special Skill:** I can juggle four objects (test me at the next biotech happy hour)



**FORESITE**CAPITAL

**Contact:** <https://www.linkedin.com/in/shoman-kasbekar/>





**Suan Tuang, MD,  
PhD**



**Bio:** Tuang is an Associate at TCG Crossover. Prior to TCGX, he joined Foresite in 2022 as an Investment Analyst on the Investment team and focuses on evaluating investment opportunities in private and public biotech companies. Before Foresite, Tuang was an Associate Research Analyst at Eventide Asset Management, where he focused on investments in small and mid-capitalization biotechnology equities across multiple therapeutic areas. He attended the Harvard/MIT MD-PhD program under the Medical Scientist Training Program (MSTP) where he received Ph.D. in Chemical Biology from MIT in 2019 and M.D. from Harvard Medical School (HST program) in 2021. During his training, he received the David H. Koch Graduate Fellowship in Cancer Research and was named Amgen Scholars “Ten To Watch.” He is also a recipient of the Paul & Daisy Soros Fellowship for New Americans. He attended MIT as an undergraduate, receiving a B.S. in Chemistry in 2014.

**Special Skill:** I am a budding songwriter.

**Contact:** <https://www.linkedin.com/in/stuang/>







**Travis Hughes,  
MD, PhD, MPH**

**DIGITALIS VENTURES**

**Bio:** Travis is a Senior Associate at Digitalis Ventures. Prior to joining Digitalis, Travis was Head of Discovery at nference, where worked to support numerous biopharma partnerships and led incubation of a company in neuro-oncology. Travis received his MD and PhD in Immunology from Harvard Medical School. During his PhD training with Alex Shalek (MIT/Broad/Ragon), he co-developed Seq-Well, a portable platform for single-cell sequencing that he deployed across numerous collaborative projects around the world. He has co-authored over 40 publications, holds multiple patents, and received numerous awards for his research. He also received his MPH in Epidemiology from the University of Michigan and graduated summa cum laude from Oklahoma Christian University with a BS in Biology.

**Notable investments:** Travis is currently a board observer at EpiBiologics and GRObio. He is also a member of the research committee at T-Therapeutics. His most recent investment was in Alterome Therapeutics.

**Special Skill:** Baking with my 3-year-old daughter, and I also make a pretty good cocktail (not for my 3-year-old).

**Contact:**

*LinkedIn*

<https://www.linkedin.com/in/travis-hughes-md-phd-mph-18a96165/>

